Compare · DXCM vs SENS
DXCM vs SENS
Side-by-side comparison of DexCom Inc. (DXCM) and Senseonics Holdings Inc. (SENS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and SENS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.58B, about 27.7x SENS ($1.07B).
- DXCM has been more active in the news (6 items in the past 4 weeks vs 4 for SENS).
- DXCM has more recent analyst coverage (25 ratings vs 7 for SENS).
- Company
- DexCom Inc.
- Senseonics Holdings Inc.
- Price
- -
- -
- Market cap
- $29.58B
- $1.07B
- 1M return
- +4.76%
- -
- 1Y return
- -8.64%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- AMEX
- IPO
- 2005
- News (4w)
- 6
- 4
- Recent ratings
- 25
- 7
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Senseonics Holdings Inc.
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to 90 and 180 days. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)
- Dexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with Diabetes
- Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
- Executive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
Latest SENS
- Director Fiorentino Edward was granted 2,635 shares, increasing direct ownership by 3% to 85,974 units (SEC Form 4)
- Director Prince Douglas S was granted 1,515 shares, increasing direct ownership by 2% to 69,331 units (SEC Form 4)
- Director Roeder Douglas A was granted 2,751 shares, increasing direct ownership by 2% to 157,238 units (SEC Form 4)
- Director Steven Edelman was granted 2,402 shares, increasing direct ownership by 3% to 91,083 units (SEC Form 4)
- Chief Medical Officer Kaufman Francine covered exercise/tax liability with 4,010 shares, decreasing direct ownership by 2% to 177,057 units (SEC Form 4) to cover taxes
- President and CEO Goodnow Timothy T covered exercise/tax liability with 32,598 shares, decreasing direct ownership by 3% to 1,143,748 units (SEC Form 4) (withholding obligation)
- GC & Corp. Development Advisor Horton Kenneth L covered exercise/tax liability with 9,545 shares, decreasing direct ownership by 3% to 285,512 units (SEC Form 4) to satisfy tax liability
- Chief Commercial Officer Hansen Brian B covered exercise/tax liability with 5,420 shares, decreasing direct ownership by 4% to 126,937 units (SEC Form 4) to satisfy tax liability
- Chief Operating Officer Jain Mukul covered exercise/tax liability with 16,194 shares, decreasing direct ownership by 3% to 500,863 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Sullivan Frederick T. covered exercise/tax liability with 5,397 shares, decreasing direct ownership by 2% to 226,477 units (SEC Form 4) to satisfy withholding obligation